journal
MENU ▼
Read by QxMD icon Read
search

American Health & Drug Benefits

journal
https://www.readbyqxmd.com/read/29910846/delayed-treatment-acceleration-in-patients-with-rheumatoid-arthritis-who-have-inadequate-response-to-initial-tumor-necrosis-factor-inhibitors-data-from-the-corrona-registry
#1
Dimitrios A Pappas, Robert A Gerber, Heather J Litman, David Gruben, Jamie Geier, Winnie D Hua, Connie Chen, Youfu Li, Joel M Kremer, John S Andrews, Jeffrey A Bourret
Background: The implementation of treat-to-target principles in rheumatoid arthritis (RA) has not been fully investigated in patients with inadequate response to tumor necrosis factor (TNF) inhibitor treatment. Objectives: To evaluate the prevalence of an inadequate response to initial TNF inhibitor treatment at 6 and 12 months among patients with RA in a real-world patient registry, as well as the delay in therapy adjustment and its impact on disease activity and patient-reported outcome (PRO) measures...
May 2018: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29910845/changes-in-medical-services-and-drug-utilization-and-associated-costs-after-narcolepsy-diagnosis-in-the-united-states
#2
Kathleen F Villa, Nancy L Reaven, Susan E Funk, Karen McGaughey, Jed Black
Background: Healthcare utilization and the cost implications associated with undiagnosed and/or misdiagnosed narcolepsy have not been evaluated, and there is scant literature characterizing the newly diagnosed population with narcolepsy with respect to treatment patterns and resource utilization. Objective: To analyze the changes in medication use, healthcare utilization, and the associated costs after a new diagnosis of narcolepsy. Methods: In this retrospective cohort study, we used data from the Truven Health Analytics MarketScan Research Databases, between January 2006 and March 2013, to identify patients who had a probable new diagnosis of narcolepsy-defined as a de novo medical claim for a multiple sleep latency test-which was preceded by ≥6 months of continuous insurance and was followed by a de novo diagnosis of narcolepsy...
May 2018: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29910844/comparing-treatment-modalities-for-end-stage-renal-disease-a-meta-analysis
#3
Gilbert L Queeley, Ellen S Campbell
Background: End-stage renal disease (ESRD) imposes significant economic and social burdens on patients and healthcare systems. In the United States alone, more than 600,000 Americans have ESRD, with an estimated annual cost of treatment of more than $30 billion. Peritoneal dialysis and hemodialysis are competing renal replacement therapies in ESRD; however, data comparing quality-of-life outcomes between these 2 modalities are limited. Objectives: To compare the effectiveness of peritoneal dialysis with the more common treatment modality of hemodialysis on the health-related quality of life (HRQoL) of patients with ESRD in the general, physical, and psychological domains; and to determine whether the time of publication and the origin of each study influenced its findings regarding the effectiveness of the 2 modalities...
May 2018: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29899815/is-adequate-nutrition-cost-effective
#4
EDITORIAL
David B Nash
No abstract text is available yet for this article.
May 2018: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29915642/patient-preferences-and-therapeutic-satisfaction-with-topical-agents-for-rosacea-a-survey-based-study
#5
Todd Williamson, Wendy Y Cheng, Nora McCormick, Francis Vekeman
Background: Rosacea is a chronic inflammatory skin disorder that primarily affects the convexities of the central face. Depending on the severity and type of rosacea, physicians may prescribe interventions such as behavioral changes, laser and intense pulsed light, as well as various pharmacologic therapies, including topical agents. The impact of side effects associated with topical treatments for rosacea on patient preferences and treatment satisfaction is not well-documented. Objective: To assess patients' concerns, treatment satisfaction, and quality of life (QOL) associated with topical treatments for rosacea...
April 2018: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29915641/effects-of-educational-messaging-on-urgent-and-emergent-care-seeking-behaviors-among-publicly-insured-populations
#6
Jesse Cambon, Tristan Cordier, Elizabeth L Munnich, Andrew Renda, Bobby Kapur, Shkelzen Hoxhaj, Meredith Williams
Background: The impact of messaging campaigns on influencing urgent care- and emergent care-seeking behaviors, including the use of in-network providers, is not well-understood. Although out-of-network healthcare utilization can have negative financial consequences for patients in narrow network Affordable Care Act plans, individuals with time-sensitive medical conditions, and especially patients visiting the emergency department, may not think about out-of-network issues. Inappropriate or avoidable emergency department visits can also create unnecessary costs for patients...
April 2018: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29915640/standardized-review-and-approval-process-for-high-cost-medication-use-promotes-value-based-care-in-a-large-academic-medical-system
#7
REVIEW
Raghu Durvasula, Janet Kelly, Anneliese Schleyer, Bradley D Anawalt, Shabir Somani, Timothy H Dellit
Background: As healthcare costs rise and reimbursements decrease, healthcare organization leadership and clinical providers must collaborate to provide high-value healthcare. Medications are a key driver of the increasing cost of healthcare, largely as a result of the proliferation of expensive specialty drugs, including biologic agents. Such medications contribute significantly to the inpatient diagnosis-related group payment system, often with minimal or unproved benefit over less-expensive therapies...
April 2018: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29899814/new-rivals-integrating-health-benefits-to-provide-comprehensive-patient-care
#8
Gary Branning, Martha Vater
No abstract text is available yet for this article.
April 2018: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29899813/20-by-2020
#9
EDITORIAL
David B Nash
No abstract text is available yet for this article.
April 2018: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29692880/healthcare-trends-for-2018
#10
F Randy Vogenberg, John Santilli
No abstract text is available yet for this article.
February 2018: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29692879/temporal-trends-in-survival-and-healthcare-costs-in-patients-with-multiple-myeloma-in-the-united-states
#11
Eric M Maiese, Kristin A Evans, Bong-Chul Chu, Debra E Irwin
Background: In recent years, the development of new therapies for multiple myeloma has improved the survival of patients, but newer treatments may also affect healthcare costs. To date, no real-world study has examined the concurrent changes in survival and total healthcare costs over time in patients with multiple myeloma. Objective: To examine the temporal changes in survival and healthcare costs among patients with multiple myeloma in the United States. Method: This retrospective claims-based cohort study is based on death files in the Truven Health MarketScan Research Commercial and Medicare Supplemental databases...
February 2018: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29692878/newly-diagnosed-hepatitis-c-in-the-us-commercially-insured-population-before-and-after-the-2012-implementation-of-expanded-screening-guidelines
#12
Bruce S Pyenson, Gabriela Dieguez, Christine Ferro, Maushumi Mavinkurve, Yuri Sanchez Gonzalez
Background: In the United States in 2014, more than 3 million individuals were estimated to have chronic hepatitis C virus (HCV) infection, including many undiagnosed individuals. In 2012, the Centers for Disease Control and Prevention expanded its HCV testing recommendations to target all adults born between 1945 and 1965, in addition to at-risk individuals, which has led to an increase in newly diagnosed patients. Few studies have explored the medical cost or clinical status of patients who are newly diagnosed with HCV...
February 2018: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29692877/predictors-of-transitioning-to-incident-chronic-opioid-therapy-among-working-age-adults-in-the-united-states
#13
J Douglas Thornton, Nilanjana Dwibedi, Virginia Scott, Charles D Ponte, Douglas Ziedonis, Nethra Sambamoorthi, Usha Sambamoorthi
Background: Opioids have been prescribed and used for chronic noncancer pain at prolific rates in the United States during the past 2 decades. Patients who transition to incident chronic opioid therapy are at increased risk for significant negative health consequences, including cardiovascular risk, endocrine disorders, opioid use disorder, and death. Objective: To identify the leading predictors associated with transitioning to incident chronic opioid therapy among working-age adults without cancer...
February 2018: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29692876/still-at-it
#14
EDITORIAL
David B Nash
No abstract text is available yet for this article.
February 2018: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29403573/comparing-the-medicaid-retrospective-drug-utilization-review-program-cost-savings-methods-used-by-state-agencies
#15
REVIEW
Sergio I Prada
Background: The Medicaid Drug Utilization Review (DUR) program is a 2-phase process conducted by Medicaid state agencies. The first phase is a prospective DUR and involves electronically monitoring prescription drug claims to identify prescription-related problems, such as therapeutic duplication, contraindications, incorrect dosage, or duration of treatment. The second phase is a retrospective DUR and involves ongoing and periodic examinations of claims data to identify patterns of fraud, abuse, underutilization, drug-drug interaction, or medically unnecessary care, implementing corrective actions when needed...
December 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29403572/amcp-nexus-2017-highlights
#16
(no author information available yet)
The following summaries represent a small sample of real-world, evidence-based information presented at AMCP Nexus 2017, October 16-19, 2017, in Dallas, TX.
December 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29403571/the-effects-of-a-sitagliptin-formulary-restriction-program-on-diabetes-medication-use
#17
Yuexin Tang, Xingyue Huang, Jinan Liu, R Ravi Shankar, Michael L Ganz, Swapnil Rajpathak
Background: Health plans have responded to the many treatment options for type 2 diabetes mellitus by implementing formulary restriction policies, including step therapy, to control costs. Little is known about the impact of step therapy programs on antidiabetes medication use. Objective: To assess the impact of a sitagliptin step therapy program on antidiabetes medication use among sitagliptin users. Methods: Using pharmacy claims from the Symphony Health Solutions' Integrated Dataverse, we compared the use of sitagliptin and other antidiabetes medications by patients enrolled in a health plan (Plan A) that implemented a sitagliptin step therapy program on July 1, 2013, with the use by patients who were contemporaneously enrolled in 2 comparison plans-Plans B and C-without step therapy programs...
December 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29403570/prospective-bundled-payments-in-a-changing-environment-the-experience-of-a-self-funded-state-sponsored-plan
#18
Frank H Lawler, Frank R Wilson, G Keith Smith, Lynn V Mitchell
Background: Healthcare reimbursement, which has traditionally been based on the quantity of services delivered, is currently moving toward value-based reimbursement-a system that addresses the quantity, quality, and cost of services. One such arrangement has been the evolution of bundled payments for a specific procedure or for an episode of care, paid prospectively or through post-hoc reconciliation. Objective: To evaluate the impact of instituting bundled payments that incorporate facility charges, physician fees, and all ancillary charges by the State of Oklahoma HealthChoice public employee insurance plan...
December 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29403569/-alexa-refill-my-omeprazole
#19
EDITORIAL
David B Nash
No abstract text is available yet for this article.
December 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29263775/the-value-of-pre-fda-approval-healthcare-economic-information-exchange-between-payers-and-drug-manufacturers
#20
Peter R Fendt, Brian Ung, F Randy Vogenberg
No abstract text is available yet for this article.
November 2017: American Health & Drug Benefits
journal
journal
48448
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"